Galapagos' Another Psoriasis Candidate Shows Efficacy, Safety Profile In Mid-Stage Study

Galapagos NV GLPG reported topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients.
At Week 4, four out of 10 patients in the high dose group had at least a 50% improvement in severity index (PASI 50) from baseline, compared to one out of 10 subjects on placebo.
No subjects achieved a PASI 50 response on the low dose of GLPG3667.
The four responders in the high dose group of GLPG3667 achieved a 52%, 65%, 74%, and 81% improvement respectively in their PASI scores from baseline, while the subject on placebo improved by 52%.
Positive efficacy signals were also observed with the high dose for other endpoints versus placebo at Week 4.
GLPG3667 was well tolerated. One patient in the low dose group interrupted the study for one day for exacerbation of psoriasis.
The majority of treatment-related adverse events were mild in nature and transient. No deaths or serious adverse events were reported.
The Company plans to initiate a global GLPG3667 Phase 2b program in psoriasis in 2022.
Related link: Galapagos SIK inhibitor failed to show positive outcomes in ulcerative colitis, rheumatoid arthritis patients
Price Action: GLPG shares are down 10.9% at $58.62 during the premarket session on the last check Thursday.